MDMA (ecstasy) enhances the extinction of fear memories in mice through a mechanism dependent on brain-derived neurotrophic factor (BDNF). When administered before extinction training, MDMA persistently improved long-term extinction of conditioned fear. The drug increased Fos expression in the amygdala and medial prefrontal cortex, while BDNF expression rose specifically in the amygdala after extinction training. Direct infusion of MDMA into the basolateral amygdala recapitulated the extinction enhancement, and blocking BDNF signaling abolished it. These findings suggest MDMA may be a useful adjunct to exposure-based therapies for PTSD and other anxiety disorders involving altered fear learning.
PTSD remains difficult to treat; only two medications are FDA-approved and have modest efficacy, and even first-line psychotherapies leave up to half of patients with persistent symptoms. Advances in neurobiology now frame PTSD as a disorder of maladaptive stress circuitry, neuroplasticity, and memory reconsolidation, opening new therapeutic possibilities. This review examines current pharmacotherapy, emerging targets, and 45 actively enrolling clinical trials. Rapid-acting interventions such as ketamine (producing symptom reductions within hours) and MDMA-assisted psychotherapy (demonstrating Phase 3 efficacy) represent major advances, though questions remain about durability, dosing, and safety. Many mechanistically plausible candidates have failed in late-stage trials due to high placebo responses, patient heterogeneity, and translational gaps.
Extinction—the process by which a learned conditioned association fades over time and with new learning—is central to fear-related disorders such as phobias, panic disorder, OCD, and PTSD, and underlies gold-standard therapies like prolonged exposure and cognitive processing therapy. Pharmacological modulators of extinction are promising treatment targets. This review covers emerging psychopharmacological agents that may facilitate extinction: D-cycloserine, scopolamine, losartan, ketamine, and MDMA. It also surveys recent advances in molecular pathways relevant to extinction and inhibitory learning, including cannabinoid, BDNF, HPA-axis signaling, and neurosteroid compounds.